PAS-21-245: Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $225,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 8 awards worth $2.5 million in total. Applications closed on September 7, 2024.
From the official notice on Grants.gov, last changed June 14, 2021. Checked November 7, 2026.
- Award ceiling$225,000
- Total funding$2.5 million
- Expected awards8
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR34
- Clinical trialsNot allowed
- Funded byNIAMS
- Median yearly award$236,140
- Typical project length3 years
- R34, Planning Grant. Planning a clinical trial: design, protocol and feasibility work before the trial itself. Other open R34 notices.
Projects funded under PAS-21-245 were run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAS-21-245 in the NIH Guide.
Key dates
| Posted | June 14, 2021 |
|---|---|
| Deadline | September 7, 2024 |
| Archived by Grants.gov | October 13, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $236,140; it allows up to $225,000 per award.
- Most of the money in the 2 programs behind this notice (68% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial not allowed)
Funded under PAS-21-245 so far
NIH funded 6 projects under PAS-21-245 in fiscal 2022 to 2026, at 6 institutions. The median yearly award was $236,140.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Integrated spatial omics to elucidate conserved inflammatory mechanisms of vesicant-induced skin injury | University of Texas Med BR Galveston | 2026 | $183,320 |
| Coordinated cytoskeletal and cell adhesion dynamics in vesicant induced skin injury | University of Chicago | 2026 | $244,000 |
| Explant human skin perfusion model to study mechanisms of chemical injury and mitigation | University of Pittsburgh at Pittsburgh | 2026 | $236,140 |
| Oxidized lipids and microvesicle particles as effectors for chemical threats to skin | Wright State University | 2025 | $225,000 |
| The Role of Macrophages in Vesicant Skin Injury and Repair | University of Illinois at Chicago | 2025 | $236,745 |
| The Initiation of Vesicant Skin Injury at a Single Cell Level | University of California-Irvine | 2024 | $157,332 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before
From fiscal 2021 to 2025, Arthritis, Musculoskeletal and Skin Diseases Research (93.846) awarded $2.6 billion across 2,897 grant awards, an average of $908,766 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 104 | $104 million |
| Brigham & Womens Hospital Inc | Massachusetts | 89 | $95.7 million |
| The Regents of the University of California, San Francisco | California | 84 | $93.3 million |
| The Washington University | Missouri | 88 | $72.4 million |
| Regents of the University of Michigan | Michigan | 73 | $68.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAS-21-245 still open?
No. It closed on September 7, 2024.
Who can apply for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)?
Closed September 7, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $225,000 each. About $2.5 million in total across about 8 awards.
Who has been funded under PAS-21-245?
NIH RePORTER lists 6 projects funded under PAS-21-245 in fiscal 2022 to 2026, at 6 institutions. The most were at University of Texas Med BR Galveston, University of Chicago, University of Pittsburgh at Pittsburgh.
Who has won Arthritis, Musculoskeletal and Skin Diseases Research grants before?
The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, The Regents of the University of California, San Francisco. The program made 2,897 awards worth $2.6 billion in that time.
Similar open grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)
- Intervention Research to Improve Native American Health (R34 Clinical Trial Optional)
- Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes (R34 - Clinical Trial Optional)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)